Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Latest Developments on GLP-1 Therapies In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the fastest-growing segments in the global pharmaceutical market....
Key Highlights: Implications: HRV Pharma is using the Shodhana alliance to turn its AI‑enabled “Virtual API” model into tangible, regulated assets, starting with a pharmaceutical...
Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
Key Highlights: Implications: With Sundae vials starting at ₹1,290 per month and a pen device to follow, Eris is leveraging Natco’s low‑cost manufacturing while using its strong diab...
Key Highlights: Implications: This curbs aggressive GLP-1 marketing (e.g., Ozempic/Wegovy), protecting India’s $115M diabetes/obesity segment from off-label hype amid 101M diabetics....
Key Highlights: Implications: Lilly’s pricing gamble carves a high-end niche, outpacing semaglutide generics from local players through clinical edge and brand power. This sets up fi...
